# A Study of SGN-ALPV in Advanced Solid Tumors

> **NCT05229900** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 43 (actual)

## Conditions studied

- Ovarian Neoplasms
- Endometrial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Stomach Neoplasms
- Gastroesophageal Junction Carcinoma
- Uterine Cervical Neoplasms
- Testicular Neoplasms

## Interventions

- **DRUG:** SGN-ALPV

## Key facts

- **NCT ID:** NCT05229900
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-21
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229900, "A Study of SGN-ALPV in Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05229900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*